Scroll Top
About Us

After a successful corporate career Mr John Hallam founded Abex Pharmaceutica (Pty) Ltd in 2006, and to this day we remain a privately-owned family-business with our roots in the South African pharmaceutical market. We are an organisation with an entrepreneurial spirit and passion for building mutually beneficial strategic partnerships, and through our commitment to excellence have been fortunate enough to grow our footprint into various international markets.

Today Abex has affiliate offices in Sydney, Shanghai, and London which include strategic joint ventures and cover our international operations in various geographies such as Europe, Africa, South East Asia, and South America. Abex is an international company based in South Africa and, actively focussed on the development, management and commercialisation of intellectual property in the healthcare field at world class standards.

We pride ourselves in our core values and in forging meaningful personal relationships with like-minded partners, which in today’s marketplace we feel has proven to be a key competitive advantage. We invite you to look through our Vision, our Values, and our Mission statement.

Respectful and strongly supportive
We respect and support one another in all we do in an open and honest environment.

Challenging in confidence and mutual trust
We will always be open to one another’s point of view and look for opportunities to change and improve in all we do.

Innovative and resourceful
We thrive on new opportunities and will always find solutions. No obstacle or problem will stop us in our quest.

Internationally aware
We have no boundaries.

Disciplined and fast
What we say, we do… and we do it reliably, faster and more effectively than anyone else.

Abex is a leading healthcare company based in South Africa and known internationally for its excellence in service, reliability, high quality, effective and innovative healthcare solutions.

Our products are clinically proven to international standards. Abex operates directly in South Africa and works internationally through the Edge Pharmaceutical group with a specific focus in Australasia, United Kingdom, China and selected European Union countries.

To provide innovative healthcare solutions so that:
EMPLOYEES wake up every day proud to go to work, have fun and learn lots of new things;

HEALTHCARE PROFESSIONALS select our products for their patients and clients with confidence;

PATIENTS recommend our products to family and friends;

PURCHASERS demand our products for their clients;

CLIENTS request our products and services and INVESTORS enjoy our business and seek long term returns.

Quality Policy Statement

Milestones

2006
Company incorporated and signed first deal
2007
Opened Abex Technical Office in Pretoria
2008
First applications for registration submitted through our subsidiary, Lasara Traders
Signed strategic consulting deal with Clicks Group to establish Unicorn
2009
Opened office in Shanghai, China
Lasara Traders obtains its licence to manufacture and import medicines from the MCC.
Formed Nucare in partnership with Carecross Health and developed first integrated e-scripting program in RSA
2010
First MA registered (Nebivolol) and licensed out
Established as professional partner of EXTEDO to provide Software Solutions for eCTD and pharmacovigilance in South Africa.
Incorporated strategic JV in Australia and New Zealand and won first major tender bid overseas.
2011
Established JV trading partnership into certain South East Asian markets.
2012
One of the first Quetiapine generics launched in South Africa.
Second to market with Sildenafil.
First major tender buyout awarded by DoH.
2014
Abex obtains its licence to import and export medicines from MCC (now SAHPRA)
First eCTD MA approved in South Africa by MCC for a generic medicine (Esomeprazole).
2015
Milestone of more than 100 approved SKUs.
2016
Signed Strategic Distribution Agreement with Clicks (Unicorn) Pharmacies.
First biosimilar Enoxaparin approved in EU and licensed out.
2017
Abex obtains Medical Device Establishment Licence from MCC
Opened office in Cyprus and United Kingdom.
Established ABEX Consumer Division and signed exclusive rights to commercialize Nasaleze in SA.
2018
Entered strategic collaboration with Pharma Dynamics to commercialize NEXA in SA.
Established strategic JV in UK for pan EU sales footprint and RnD cooperation
First MA approved in UK (Gabapentin)
Acquired operating company approved by TGA in Australia
2019
Launched five non-prescription Consumer Health brands into SA market.
Signed exclusive partnership with Enzymatica for the commercialization of ColdZyme in Australia and New Zealand.
2024
Achieved ISO 9001 and ISO 13485 certification